Hello, in watching the videos on acquired resistance with ALK + targeted therapies, there was one where Dr. Alice Shaw spoke, whereby she was mentioning some of the ALK+ genomic alterations and which drugs are not effective for certain mutations, and certain drugs that were. Recently my biopsy was sent to Foundation for molecular testing and came back ALK+ EML4-ALK fusion, "L1196Q". I was hoping that the report from Foundation would pinpoint which targeted therapies would be effective for this specific ALK+ genomic alteration, but is just listed the ALK+ inhibitor drugs Alectinib, Crizotinib, Brigatinib, Ceritinib. I have been on Alectinib for a year and a half, and crizotinib for 14 months before that. Recent progression to mediastinal lymph nodes causes my oncologist to suspect acquired resistance now to alectinib.
Is there any way to find out which targeted therapy drug listed in the report would be the correct therapy for the specific alteration identified?
(This month marks my 4 year survivor anniversary and I look forward to many more.)